In preclinical glioma models, these triple-edited CAR T cells exhibited enhanced antitumor activity, elevated Th1 cytokine secretion (IFN-γ, TNF-α), and improved persistence following repeated antigen stimulation. The gene discussed is TNF; the disease is glioma.